The first treatment of rheumatoid arthritis should be on general lines, with rest, physical treatment and salicylates; next may come a choice between the use of gold and antimalarials. They both act slowly and for some period after cessation, and both, unlike steroids, appear to affect the rheumatoid factor advantageously and only slowly the sedimentation rate. They are both toxic to some patients. In a different category are the steroids and corticotrophin, which-temporarily control the inflammatory reaction and may sometimes be used together with the gold or antimalarial. Page (1951) reported improvement in arthritic symptoms in cases of systemic lupus treated with mepacrine, and was followed by a report from Steck et al. (1952) . Reports on the efficacy and toxicity of various antimalarials have since been published in a steady flow. The margin between therapeutic and toxic dosage is always small, but with the less toxic compounds, such as hydroxychloroquine, the main anxiety has been ophthalmic complications. In 1946 Dame noted transient visual-field changes in patients under treatment with mepacrine. Hobbs & Calnan (1958) and Zelba & Diering (1958) Bagnall (1960) and Kersley & Palin (1959) a large proportion. Toxicity, excluding ophthalmic, is found to a slight degree in some 20-25% of cases. The symptoms can to some extent be grouped into (1) early, mainly consisting of gastro-intestinal disturbance, malaise and depression, which frequently wear off, and (2) later, skin rashes requiring discontinuation of treatment. It is of interest that early 'toxic' symptoms occurred in Mainland & Sutcliffe's series in the trial and in the placebo group in a ratio of 3 to 2. Kersley & Palin found that many patients transferred from the antimalarial to control tablets thought that-they were being given a tonic, suggesting that they were previously slightly toxic. Bartholomew & Duff (1963) found a rise in SGOT in 4 out of 15 patients on amodiaquine hydrochloride 150 mg. Mainland & Sutcliffe noted a significant improvement in the latex test in the treated in comparison with the control group, and Baumer (1963) found less osteoporosis in those treated.
The ophthalmic complications also fell into two so far unrelated groups: (1) The early corneal opacities and (2) late retinal damage. Zva fler et al. (1962) showed in experiments with rats that chloroquine was deposited in the cornea, iris, choroid and pigment of the retina. The earliest corneal changes, only visible as dots, or later as lines, just under the surface and just below the centre of the cornea, are only seen on slit-lamp examination and may occur after about a month, often when the therapeutic effect is Just being felt. Kersley & Palin (1959) (Schmidt & Miiller-Limmroth 1962) and, more easily and quickly determined, by the EOG (Arden et al. 1962) . By this latter technique changes in the corneo-fundal potential are recorded during light adaptation.
Taking into consideration the benefits and dangers, anti-malarial therapy may still certainly be considered as an alternative to aurotherapy and is particularly valuable when renal lesions contraindicate the use of gold. It was natural that anabolic steroids should be tried in combination with corticosteroids in the treatment of rheumatoid arthritis in an attempt to prevent or reverse steroid osteoporosis. Several reports (Spilborghs 1962 , Caruso et al. 1962 , Clark & Mills 1962 , Katona et al. 1963 ) have now appeared which claim a synergistic effect between the two, enabling the dose of corticosteroid to be reduced without change in the clinical state. It is with this aspect that we wish to deal.
The only report in English literature is that by Clark & Mills (1962) . They treated two groups of patients. The first group of 12 patients they described as steroid intoxicated. Eleven of these were admitted to hospital. They were given 15 mg methandrostenolone daily and the average daily dose of prednisone was reduced from 15 2 mg to 4*2 mg over six weeks. Bed rest may have played some part in this, and so they treated a second group of 12 outpatients in an open trial, giving 10 mg methandrostenolone daily for six weeks.
The average dose of prednisone fell from 8&5 mg to 6 mg daily and the Lansbury systemic index from 78 to 48 (Lansbury 1958) . On discontinuation of the anabolic steroid the index rose to 68 on the same corticosteroid dose. On restarting anabolic steroid, however, the index fell only to 60. Katona et al. (1963) have reported their work on the combination of paramethasone and oxymetholone in the therapy of rheumatoid arthritis. It was suggested that the dose of paramethasone can be reduced and with it the side-effects of longterm steroid therapy; a dose reduction of 40-4 % was achieved in the group treated with oxymetholone compared with the controls. Their paper appeared after the trial which is the subject of our report but prompted us to think that it might be worth while to give the results of a doubleblind trial in which a cross-over pattern was employed and which extended over a longer period.
Material and Methods
Patients were selected for this trial who had been on a stable dose of corticosteroid for at least six months prior to entry. Two initial assessments were made at monthly intervals before starting treatment with anabolic steroid and one assessment was made a month after completion of the trial. The patients were observed at intervals of one month during the trial. Three months were allowed for placebo treatment and three months for active treatment. It was hoped that by using a long period of observation the effect of spontaneous remission and relapse would be diminished.
The anabolic steroid selected was oxymetholone in a dosage of 7-5 mg per day. This dose was chosen as the result of previous studies by Gomez-Mont & Lasso (1960) and Myerson (1961) to determine the optimum anabolic dosage.
Sixteen patients entered the trial. One had polymyositis and was included as a matter of interest but was not assessable. One patient, who had received placebo only, developed jaundice and was withdrawn from the trial; another, aged 81, also on placebo, died from bronchopneumonia during the second month of the trial.
Of the 13 patients who completed the period of observation 9 were women and 4 men, of average age 57-7 years (range 45-75 years) and the average duration of rheumatoid arthritis before entry into the trial was six and a half years (range two to fifteen years). Steroid therapy had been administered for an average period of 23 4 months (range six months to five years).
